^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Signal-X™

    Company:
    Universal DX
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    over1year
    Universal DX presents data from large, 1,000-patient, multi-cohort study proving 93% sensitivity for colorectal cancer and 54% sensitivity for advanced adenoma at 92% specificity (Universal DX Press Release)
    "Universal Diagnostics...announced the results of a large international multi-cohort case-control study, which demonstrate that cell-free DNA methylation and fragmentation signals combined with machinelearning can be used to detect early-stage colorectal cancer (CRC) with 93% and pre-cancerous advanced adenomas (AA) with 54% sensitivity at 92% specificity."
    Clinical data
    |
    Signal-X™